Bionano Genomics (BNGO) EBT (2017 - 2026)

Bionano Genomics has disclosed EBT across 10 years of filings, most recently posting -$8.3 million for Q1 2026.

• EBT for Q1 2026 came in at -$8.3 million, down 167.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.5 million (up 62.5% YoY), and the FY2025 annual result was -$26.3 million, up 76.58% from the prior year.
• EBT came in at -$8.3 million for Q1 2026 at Bionano Genomics, down from -$7.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$3.1 million in Q1 2025 to a low of -$112.5 million in Q3 2023.
• The 5-year median for EBT is -$31.4 million (2024), against an average of -$30.0 million.
• Across the five-year window, EBT plunged 254.07% in 2023 and surged 90.16% in 2025, its largest moves.
• Bionano Genomics' EBT stood at -$36.9 million in 2022, then decreased by 19.13% to -$43.9 million in 2023, then jumped by 53.19% to -$20.6 million in 2024, then surged by 61.59% to -$7.9 million in 2025, then declined by 5.0% to -$8.3 million in 2026.
• The last three EBT figures came in at -$8.3 million (Q1 2026), -$7.9 million (Q4 2025), and -$8.5 million (Q3 2025), per Business Quant data.